KYMR FY 2025 Earnings — Kymera Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

KYMRKymera Therapeutics, Inc.

$7B

FY 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$39M-16.7% YoY

Gross Profit

$39M100.0% margin

Operating Income

-$349M-891.3% margin

Net Income

-$311M-794.4% margin

EPS (Diluted)

$-3.69

Cash Flow

Operating Cash Flow

-$233M

Free Cash Flow

-$234M

Stock-Based Comp.

$60M

Balance Sheet

Total Assets

$1.7B

Total Liabilities

$163M

Stockholders' Equity

$1.6B

Cash & Equivalents

$357M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$39M	$47M	-16.7%
Gross Profit	$39M	$47M	-16.7%
Operating Income	-$349M	-$262M	-33.5%
Net Income	-$311M	-$224M	-39.1%